$0.18 EPS Expected for CTI BioPharma Corp. (NASDAQ:CTIC) This Quarter

Brokerages expect CTI BioPharma Corp. (NASDAQ:CTICGet Rating) to announce earnings per share of $0.18 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for CTI BioPharma’s earnings, with the highest EPS estimate coming in at $0.38 and the lowest estimate coming in at ($0.02). CTI BioPharma reported earnings of ($0.23) per share in the same quarter last year, which would suggest a positive year over year growth rate of 178.3%. The company is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that CTI BioPharma will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to $0.26. For the next fiscal year, analysts anticipate that the business will post earnings of $0.30 per share, with EPS estimates ranging from $0.09 to $0.50. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for CTI BioPharma.

CTI BioPharma (NASDAQ:CTICGet Rating) last posted its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.10).

CTIC has been the topic of a number of analyst reports. Brookline Capital Acquisition upped their price target on shares of CTI BioPharma from $7.20 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, March 1st. StockNews.com started coverage on shares of CTI BioPharma in a report on Thursday, March 31st. They issued a “sell” rating for the company. Brookline Capital Management upped their price target on CTI BioPharma from $7.20 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, March 1st. JMP Securities increased their target price on CTI BioPharma from $4.00 to $5.00 and gave the company a “market outperform” rating in a research report on Wednesday, March 2nd. Finally, Needham & Company LLC increased their target price on CTI BioPharma from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.21.

NASDAQ:CTIC traded down $0.06 during trading hours on Wednesday, hitting $4.75. The company had a trading volume of 139,162 shares, compared to its average volume of 4,763,344. CTI BioPharma has a 52 week low of $1.43 and a 52 week high of $5.25. The firm has a market cap of $474.61 million, a P/E ratio of -4.08 and a beta of 1.11. The company’s 50-day simple moving average is $3.52.

A number of large investors have recently modified their holdings of the business. Northern Trust Corp raised its position in CTI BioPharma by 7.5% in the 4th quarter. Northern Trust Corp now owns 135,693 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 9,434 shares in the last quarter. Qube Research & Technologies Ltd raised its position in CTI BioPharma by 52.4% in the 4th quarter. Qube Research & Technologies Ltd now owns 37,626 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 12,938 shares in the last quarter. Jane Street Group LLC acquired a new stake in CTI BioPharma in the 3rd quarter valued at about $51,000. Barclays PLC raised its position in CTI BioPharma by 365.8% in the 3rd quarter. Barclays PLC now owns 26,108 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 20,503 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in CTI BioPharma by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 682,626 shares of the biopharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 23,800 shares in the last quarter. Institutional investors own 52.27% of the company’s stock.

About CTI BioPharma (Get Rating)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.

Featured Articles

Get a free copy of the Zacks research report on CTI BioPharma (CTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.